AstraZeneca Plc (AZN)-Medical Equipment-Deals and Alliances Profile

AstraZeneca Plc (AZN)-Medical Equipment-Deals and Alliances Profile


  • Products Id :- GDME3904D
  • |
  • Pages: 136
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

AstraZeneca plc (AstraZeneca) is a biopharmaceutical company that endeavors to discover, produce and commercialize a wide range of prescription drugs. It focuses on therapy areas such as respiratory; cardiovascular and metabolic disease (CVMD); and cancer, besides autoimmune, infection and neurological diseases. The company's product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies and through distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, the UK.

AstraZeneca Plc (AZN)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company financial deals that enable you to understand the company expansion/divestiture and fund requirements

The profile enables you to analyze the company financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company business segments' expansion / divestiture strategy

The profile presents deals from the company core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

AstraZeneca Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 8

AstraZeneca Plc, Medical Equipment Deals By Type, 2011 to YTD 2017 9

AstraZeneca Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 10

AstraZeneca Plc, Medical Equipment, Deals By Market, 2011 to YTD 2017 11

AstraZeneca Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 12

AstraZeneca Plc, Medical Equipment, Deal Details 15

Venture Financing 15

Definiens Raises USD20.3 Million in Venture Financing Round 15

CeraPedics Raises US$19 Million In Series C Financing 16

Definiens Raises US$13 Million In Venture Financing 17

Ambit Biosciences Secures US$30 Million In Series D-2 Financing 18

Partnerships 19

AstraZeneca Enters into Licensing Agreement with Pelago Bioscience 19

AstraZeneca Enters into Agreement with Genedata 20

Neoprobe Enters Into Licensing Agreement With AstraZeneca 21

Trovagene Enters into Agreement with AstraZeneca 22

AstraZeneca Enters into Partnership with DNAnexus 23

NeoGenomics and Definiens Enter into Agreement 24

SenzaGen Enters into Agreement with AstraZeneca 24

AgPlus Diagnostics Enters into Agreement with AstraZeneca 25

Indivumed Partners with Definiens 25

Foundation Medicine Enters into Agreement with AstraZeneca 26

Definiens Partners with MolecularMD 27

MedImmune Enters into Agreement with Genisphere 28

Human Longevity Partners with AstraZeneca 28

PROOF Centre Partners with AstraZeneca 29

HighRes Biosolutions Enters into Agreement with AstraZeneca 30

Labcyte Enters into Agreement with AstraZeneca 31

AstraZeneca Enters into Research Agreement with Sutter Health 32

Myriad Genetics Expands Agreement with AstraZeneca 33

Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 33

AstraZeneca Enters into Co-Development Agreement with Qiagen 34

AstraZeneca Enters into Co-Development Agreement with Roche 35

Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK 36

Ventana Medical Enters into Co-Development Agreement with MedImmune 37

Definiens Enters Into Agreement With Metamark For ProMark Prognostic Test 38

Myriad Genetics Expands Agreement with AstraZeneca for Olaparib 39

Oxford Cancer Biomarkers Enters Into Agreement With AstraZeneca For Biomarker Discovery 39

AstraZeneca Enters Into Research Agreement With Karolinska Institutet 40

Metamark Genetics Enters Into Co-Development Agreement With Definiens 41

Life Technologies, Oxford Biomedical Research Centre, AstraZeneca And ORD Enter Into Co-Development Agreement 42

Leica Microsystems Enters Into Co-Marketing Agreement With Definiens 42

Definiens Enters Into An Agreement With Cernostics 43

Advanced Cell Diagnostics Enters Into Co-Development Agreement With Definiens 44

Merger 45

AstraZeneca Rumored To Merge With Amgen 45

Debt Offering 46

AstraZeneca Prices Private Placement of 0.875% Notes Due 2021 46

Acquisition 47

Pfizer May Increase Bid to Acquire AstraZeneca 47

MedImmune Acquires Definiens for USD150 Million 49

AstraZeneca Rumored To Acquire Forest Labs For US$15 Billion 50

Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 50

AstraZeneca To Acquire Remaining 10% Stake In Astrazeneca Pharma India 52

DENTSPLY International Acquires Astra Tech From AstraZeneca For US$1,800 Million 53

AstraZeneca Plc-Key Competitors 55

Key Employees 56

Locations And Subsidiaries 58

Head Office 58

Other Locations & Subsidiaries 58

Recent Developments 64

Strategy And Business Planning 64

Apr 25, 2017: AstraZeneca marks a key milestone with the 'topping out' of new global R&D centre and HQ in Cambridge, UK 64

Apr 04, 2016: Heptares Joins Pharma Consortium Applying State of the Art Cryo-Electron Microscopy to Advance Structure Based Drug Discovery 66

Financial Announcements 67

Apr 27, 2017: AstraZeneca Announces Q1 2017 Results 67

Feb 02, 2017: Astrazeneca Announces Full-Year and Q4 2016 Results 68

Nov 10, 2016: AstraZeneca: Year-To-Date and Q3 2016 Results 69

Jul 28, 2016: AstraZeneca: H1 2016 Results 81

Apr 29, 2016: AstraZeneca announces 1st Quarter 2016 Results 92

Apr 29, 2016: AstraZeneca Announces Q1 2016 Results 103

Feb 04, 2016: Full-Year and Q4 2015 Results 105

Feb 04, 2016: AstraZeneca Full-Year and Q4 2015 Results 107

Corporate Communications 120

Jun 29, 2017: Astra Zeneca: Outcome of the meeting of board of directors held on June 29, 2017 120

May 31, 2017: AstraZeneca appoints Professor Nazneen Rahman to its Board of Directors and Science Committee 121

Mar 06, 2017: Changes to AstraZeneca Board of Directors 122

Nov 09, 2016: Change To Astrazeneca Board Of Directors 123

Sep 28, 2016: Change To Astrazeneca Board Of Directors 124

Product News 125

Sep 20, 2016: Can drag and drop cancer simulation speed up drug discovery 125

Aug 08, 2016: AstraZeneca Diabetes Diet and Lifestyle Support Program, Fit2Me, Extends to Include Cardiovascular Health 127

May 27, 2016: Blood test supports use of potential new treatment for patients with stomach cancer 128

May 05, 2016: Preliminary results comparing PD-L1 IHC diagnostic assays in lung cancer released 130

Feb 16, 2016: Data analysis platform driving preclinical modelling capabilities in AstraZeneca launched to wider pharmaceutical industry 131

Other Significant Developments 132

Jun 06, 2017: AstraZeneca Selects ArisGlobal LifeSphere Safety-Risk Management 132

Mar 31, 2017: First Collaborative Definition of Patient Centricity, Co-created by AstraZeneca with Patients and Carers, Is Published in British Medical Journal 133

Nov 29, 2016: Cytel and AstraZeneca Early Clinical Development Software Collaboration Facilitates Clinical Development Decision-Making 134

Sep 21, 2016: AstraZeneca Selects LLamasoft as Supply Chain Design Partner of Choice 135

Appendix 136

Methodology 136

About GlobalData 136

Contact Us 136

Disclaimer 136

List of Figures

AstraZeneca Plc, Medical Equipment, Deals by Type, 2011 to YTD 2017 1

AstraZeneca Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 1

AstraZeneca Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 1

AstraZeneca Plc, Medical Equipment, Deals By Market, 2011 to YTD 2017 1

AstraZeneca Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 8

AstraZeneca Plc, Medical Equipment, Deals by Type, 2011 to YTD 2017 9

AstraZeneca Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 10

AstraZeneca Plc, Medical Equipment, Deals by Market, 2011 to YTD 2017 11

List of Tables

AstraZeneca Plc, Medical Equipment, Key Facts, 2016 1

AstraZeneca Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 1

AstraZeneca Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 8

AstraZeneca Plc, Medical Equipment Deals By Type, 2011 to YTD 2017 9

AstraZeneca Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 10

AstraZeneca Plc, Deals By Market, 2011 to YTD 2017 11

AstraZeneca Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 12

Definiens Raises USD20.3 Million in Venture Financing Round 15

CeraPedics Raises US$19 Million In Series C Financing 16

Definiens Raises US$13 Million In Venture Financing 17

Ambit Biosciences Secures US$30 Million In Series D-2 Financing 18

AstraZeneca Enters into Licensing Agreement with Pelago Bioscience 19

AstraZeneca Enters into Agreement with Genedata 20

Neoprobe Enters Into Licensing Agreement With AstraZeneca 21

Trovagene Enters into Agreement with AstraZeneca 22

AstraZeneca Enters into Partnership with DNAnexus 23

NeoGenomics and Definiens Enter into Agreement 24

SenzaGen Enters into Agreement with AstraZeneca 24

AgPlus Diagnostics Enters into Agreement with AstraZeneca 25

Indivumed Partners with Definiens 25

Foundation Medicine Enters into Agreement with AstraZeneca 26

Definiens Partners with MolecularMD 27

MedImmune Enters into Agreement with Genisphere 28

Human Longevity Partners with AstraZeneca 28

PROOF Centre Partners with AstraZeneca 29

HighRes Biosolutions Enters into Agreement with AstraZeneca 30

Labcyte Enters into Agreement with AstraZeneca 31

AstraZeneca Enters into Research Agreement with Sutter Health 32

Myriad Genetics Expands Agreement with AstraZeneca 33

Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 33

AstraZeneca Enters into Co-Development Agreement with Qiagen 34

AstraZeneca Enters into Co-Development Agreement with Roche 35

Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK 36

Ventana Medical Enters into Co-Development Agreement with MedImmune 37

Definiens Enters Into Agreement With Metamark For ProMark Prognostic Test 38

Myriad Genetics Expands Agreement with AstraZeneca for Olaparib 39

Oxford Cancer Biomarkers Enters Into Agreement With AstraZeneca For Biomarker Discovery 39

AstraZeneca Enters Into Research Agreement With Karolinska Institutet 40

Metamark Genetics Enters Into Co-Development Agreement With Definiens 41

Life Technologies, Oxford Biomedical Research Centre, AstraZeneca And ORD Enter Into Co-Development Agreement 42

Leica Microsystems Enters Into Co-Marketing Agreement With Definiens 42

Definiens Enters Into An Agreement With Cernostics 43

Advanced Cell Diagnostics Enters Into Co-Development Agreement With Definiens 44

AstraZeneca Rumored To Merge With Amgen 45

AstraZeneca Prices Private Placement of 0.875% Notes Due 2021 46

Pfizer May Increase Bid to Acquire AstraZeneca 47

MedImmune Acquires Definiens for USD150 Million 49

AstraZeneca Rumored To Acquire Forest Labs For US$15 Billion 50

Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 50

AstraZeneca To Acquire Remaining 10% Stake In Astrazeneca Pharma India 52

DENTSPLY International Acquires Astra Tech From AstraZeneca For US$1,800 Million 53

AstraZeneca Plc, Key Competitors 55

AstraZeneca Plc, Key Employees 56

AstraZeneca Plc, Subsidiaries 58

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AstraZeneca Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16020
Site License
USD 500 INR 32040
Corporate User License
USD 750 INR 48060

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com